Abstract. Colestimide is a new anion-exchange resin used to lower serum cholesterol in Japan. Because of its excellent compliance, colestimide can replace cholestyramine. To clarify the effect of colestimide on glycemic controls, colestimide (3 g/day) or pravastatin (10 mg) was given orally to patients with type 2 diabetes treated with oral hypoglycemic agents or insulin who had low-density lipoprotein (LDL) cholesterol levels exceeding 3.6 mmol/l. In the colestimide groups, fasting plasma glucose concentrations had decreased significantly from 8.5 ± 1.4 to 7.7 ± 1.5 mmol/l at 3 months (P<0.05), as had glycated hemoglobin (HbA 1c ) from 7.7 ± 0.7% to 6.8 ± 0.5%, for an 8% reduction (P<0.01). Fasting plasma glucose and HbA 1c did not change in the pravastatin group. Total cholesterol and LDL-cholesterol decreased significantly (P<0.01) with either medication, with similar reduction rates for both drugs. Doses of oral hypoglycemic agents and insulin did not change during the study, and body weight remained stable. Considering that patients with type 2 diabetes often have hyperlipidemia, colestimide therapy may have a clinically useful dual action in such patients.
LOW density lipoprotein cholesterol (LDLc) is the most prominent risk factor for coronary artery disease in patients with type 2 diabetes mellitus [1] . Recent widely use of hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) for the treatment of hyperlipidemia has reduced mortality and incidence of cardiovascular disease in patients with type 2 diabetes mellitus [2, 3] .
Although bile acid sequestrants are effective in reducing LDLc in patients with various forms of primary hypercholesterolemia [4] , they have not been prescribed widely to reduce LDLc in patients with type 2 diabetes mellitus. Obstacle to their use include the predisposition of patients with type 2 diabetes mellitus toward hypertriglyceridemia [5] , and poor patient tolerance of the drug.
Colestimide is a new anion exchange resin which has shown strong hypolipidemic effects in rabbits [6] . In addition, because it is associated with patient compliance [7] , colestimide has essentially replaced cholestyramine in the treatment of hypercholesterolemia in Japan. Cholestyramine is reported to reduce blood glucose, but the effect of colestimide on glycemic control in diabetic patients has not been reported.
The risk of a major coronary event has been shown to be as high in diabetic subjects without clinically manifest coronary heart disease as in nondiabetic patients who previously have experienced a myocardial infarction. Data from large intervention studies like the Collaborative Atorvastatin Diabetes Study (CARDS) have demonstrated an absolute risk reduction in coronary events resulting from statin treatment in diabetic patients [8] . As a consequence, statin treatment is being advocated as a first priority in metabolic control for diabetic dyslipidemic patients.
Recently, however, a high dose of atorvastatin was reported to have an that adverse effect on glycemic control [9, 10] . In addition, we also showed that a low dose of atorvastatin had an adverse effect on gycemic control in Japanese diabetic patients [11] . On the other hand, the West of Scotland Coronary Prevention Study found that pravastatin therapy reduced the risk of becoming diabetic by 30% [8] . Thus, the effects on glycemic control appear to differ between individual statins. In diabetic patients with dyslipidemia, one needs to select an antilipidemic drug that does not adversely affect glycemic control. In that context, several studies have found that pravastatin did not adversely impact glycemic control [9, 11, 12] .
Therefore, the primary objective of this study was to compare the effects of colestimide and pravastatin on glycemic control in patients with type 2 diabetes mellitus.
Materials and Methods
Type 2 diabetic patients with hyperlipidemia were recruited for this study, which was approved by the Yokohama City University Medical Center Research Committee. All participants gave their written informed consent. Complete physical examination, electrocardiography, and laboratory evaluation were performed for each patient during screening. Patients were eligible for study if glycated hemoglobin (HbA 1c ) values were between 6.5 and 9.0% at entry, treatment of type 2 diabetes required oral hypoglycemic agents or insulin, and LDLc concentrations exceeded 3.6 mmol/l. The study included 70 outpatients, 30 to 75 years old, who had been diagnosed with type 2 diabetes and had been followed up monthly for over 1 year.
Patients with severe diabetic complications such as retinopathy, nephropathy, neuropathy, or ischemic heart disease were excluded. During 3 months of observation, patients who showed unstable glycemic control, and showed more than 10% variation from their initial HbA 1c value also were excluded. Patients were randomized pairwise according to the order in which each originally presented to begin with the trial; one was given, oral colestimide (3 g twice daily), and the other, pravastatin (10 mg once daily).
After 3 months of administration of colestimide or pravastatin, several clinical indices (fasting plasma glu- [HDLc] ) were compared between groups to evaluate the two treatments. All subjects were encouraged to maintain their usual diet and physical activity. Doses of all oral hypoglycemic agents or insulin were not changed during this study. In addition, all medications known to influence glucose tolerance or lipid metabolism were neither added nor withdrawn during the study.
Statistical analysis
We carried out repeated-measure analysis of variance to assess the effect of the order of patients randomization to pravastatin or colestimide and the overall effect of colestimide therapy. P values less than 0.05 were considered statistically significant.
Results

Baseline characteristics of randomized patients
We randomized 70 patients to the pravastatin or colestimide treatment group (each n = 35). As shown in Table 1 , the groups showed no significant differ- served as early as 1 month after initiating colestimide treatment, persisting for 3 months of observation (0 months, 8.5 ± 1.4 mmol/l; 1 month, 7.94 ± 1.0; 2 months, 7.8 ± 1.3; and 3 months, 7.7 ± 1.5). After 3 months, FPG concentrations still were significantly decreased (by 8%, P<0.01) in the colestimide-treated group, in contrast to no significant change in pravastatintreated group. FPG still did not differ between groups. HbA 1c reduction also was observed as early as 1 month after colestimide treatment, persisting for 3 months of observation (0 months, 7.7 ± 0.7%; 1 month, 7.4 ± 0.7%; 2 months, 7.0 ± 0.6%; and 3 months, 6.8 ± 0.5%).
With colestimide treatment, HbA 1c had decreased significantly at 3 months (by 8% of the baseline value, P<0.01; Fig. 1 ). Given the importance of long-term effect of colestimide on glycemic control, we compared HbA 1c at 6 months after treatment although numbers of subjects were slightly decreased at that time point. HbA 1c at 6 months also was significantly decreased (6.7 ± 0.7, P<0.01). Pravastatin had no significant effect on HbA 1c at 1, 2, 3, or 6 months; the change differed significantly between groups (P<0.001). Unlike FPG, HbA 1c differed significantly between groups after treatment. The proportion of patients treated with colestimide who achieved an HbA 1c reduction of 1 percentage point or more from baseline was 10%; for the pravastatin-treated group, this proportion was 0%. Body weight was unchanged during the observation period and showed no significant difference between the two medications. As shown in Table 2 , TC and LDLc was decreased significantly (P<0.01) by either medication. The reduction rate was similar between medications. TG increased slightly in the colestimide group (from 7.2 ± 3.1 to 8.2 ± 3.4 mmol/l; n.s.) and decreased slightly in the pravastatin group (from 8.2 ± 3.8 to 7.4 ± 3.7 mmol/l; n.s.). The change did not differ significantly between medications. HDLc was not changed by treatment in either group. No adverse trends were apparent in vital signs, physical examination findings, heart rate, or blood pressure in either treatment group.
To investigate the mechanisms of HbA 1c reduction by colestimide, we measured plasma glucose and serum insulin in colestimide-treated patients (n = 15). We then calculated HOMA-IR [13] , an established index of insulin resistance, before and after colestimide treatment. HOMA-IR decreased from 3.7 ± 2.0 to 2.6 ± 1.3 after 3 months of colestimide treatment, but the reduction fell short of significance.
In addition, to elucidate whether or not the glucoselowering action of colestimide was dependent on its cholesterol-lowering action, we compared the HbA 1c reduction rate/LDLc reduction rate between colestimide and pravastatin treatments. This ratio was much higher in the colestimide group (0.7) than in the pravastatin group (0.08).
Discussion
Studies have found that cholestyramine reduced blood glucose. However, no previous studies had examined the hypoglycemic effect of colestimide, a new anion exchange resin, in type 2 diabetes. In the current study, we examined the effects of colestimide and pravastatin on glycemic control. Colestimide improved glycemic control significantly in diabetic patients, and was effective when given either by itself or in combination with previous medications including multiple antihyperglycemic agents.
Specific mechanisms by which colestimide lowered blood glucose are important to identify. The lipidlowering effect of colestimide was slightly weaker than that of pravastatin, but not significantly, while pravastatin treatment had no effect on blood glucose. On the other hand, the HbA 1c reduction rate/LDLc reduction rate was decidedly higher in the colestimide group. These results suggest that the glucose-lowering action of colestimide is independent of its cholesterol-lowering action. Colestimide treatment slightly decreased HOMA-IR, suggesting that reduction of HbA 1c with colestimide might be in part mediated through improvement of insulin sensitivity.
Colestimide has been confirmed to pass unabsorbed through the intestinal tract, while cholestyramine slightly suppresses postprandial glycemia in normal volunteers without interfering with gastrointestinal transient time or xylose absorption. Furthermore, it has been reported that intestinal sugar transports are increased in diabetic patients [14] . Cholestyramine, therefore, might improve glycemic control in diabetic patients by decreasing abnormally excessive intestinal sugar absorption, although the precise mechanism awaits further investigation. Recently, the farnesoid X receptor (FXR), a member of the nuclear receptor superfamily, has been reported to take part in regulating carbohydrate metabolism [15] . Stayrook et al. showed that FXR agonists increased PEPCK, a key rate-limiting steps in gluconeogenesis, expression as well as glucose production from primary hepatocytes [15] . Since colestimide, resin acts as an antagonist ligand at the FXR [16, 17] , we can hypothesize that colestimide may inhibit gluconeogenesis mediated through the decreased expression of PEPCK via FXR receptor inhibition.
Watanabe et al. recently reported that bile acids induce energy expenditure by promoting intracellular thyroid hormone activation [18] . They demonstrated that administration of bile acids, especially cholic acids, increased energy expenditure in brown adipose tissue, preventing obesity and resistance to insulin. This metabolic effect is critically dependent on induction of a cyclic-AMP-dependent thyroid hormoneactivating enzyme, type 2 iodothyronine deiodinase (D2). Colestimide is reported to increase cholic acid content among bile acids [19] . One reasonable hypothesis concerning improvement of glycemic control by colestimide therefore might involve cholic aciddependent D2 activation.
Colestimide, which has a mechanism of action differing from that of HMG-CoA inhibitors and is not absorbed in the body, is considered to be an important addition to treatment options for hypercholesterolemia. Rhabdomyolysis, severe side effect of statins, precludes their use in renal insufficiency, while colestimide is safe in such circumstances.
Results from the U.K. Prospective Diabetes Study [20] [21] [22] , have demonstrated that reductions in HbA 1c can lower risk of microvascular complications. Unfortunately, glycemic control in type 2 diabetic patients with hypercholesterolemia often is inadequate. In addition, many treatments intended to improve control may not be tolerated by substantial numbers of patients or have undesirable side effects such as weight gain, hypoglycemia, and edema; these can impede the attainment of glycemic control and discourage patient compliance [20] [21] [22] [23] . For example, prolonged sulfonylureainduced hypoglycemia has occurred in patients with end-stage renal disease [24] , and metformin is contraindicated in patients prone to lactic acidosis such as those with hepatic or renal insufficiency. New drugs suitable for use by patients with hepatic or renal insufficiency clearly are needed. As previously described, colestimide is safe in such patients. In addition, cholestyramine has been reported to decrease incidence of coronary heart disease [4, 25] . Colestimide shows potential for improving outcome in patients with both diabetes and hyperlipidemia: two major risk factors for atherosclerotic disease.
In the West of Scotland Coronary Prevention Study, pravastatin therapy reduced the risk of becoming diabetic by 30% [12] . However, pravastatin had no hypoglycemic effect on patients with type 2 diabetes. As patients with type 2 diabetes often also have hyperlipidemia, colestimide may be considered clinically useful for glycemic control in these patients through its dual actions.
In conclusion, colestimide therapy in patients with type 2 diabetes mellitus effectively reduced HbA 1c as well as LDL cholesterol during a 3-month period. Long-term efficacy of colestimide therapy requires further evaluation.
